Objective: Antiretroviral therapy (ART) may interfere with replication of hepatitis B virus (HBV), raising the hypothesis that HBV infection might be prevented by ART. We investigated the incidence and risk factors associated with HBV among HIV-infected adults in Rakai, Uganda.
Introduction
Both HIVand hepatitis B virus (HBV) are highly endemic in sub-Saharan Africa (SSA). According to the 2014 United Nations Programme on HIV and AIDS report, 70% of the global HIV disease burden (36.9 million) is in this region [1] , which also has the second highest number of individuals with chronic HBV infection (15% of the 350-400 million) in the world [2, 3] . Globally, coinfection with HBV is common among HIV-infected patients, and accelerates the progression of liver disease to cirrhosis, end-stage liver disease, and liver cancer, thereby threatening to reverse the survival benefit that has been derived from the scale-up of antiretroviral therapy (ART) [4, 5] . There are also data that suggest that HBV may accelerate HIV progression in SSA [6] . Among MSM and intravenous (i.v.) drug users in the United States, there is a strong association between the incidences of both HIV and HBV [7] . This association is, however, less clear in SSA where HIV is predominantly transmitted via the heterosexual route and HBV horizontally during childhood [8, 9] . Data on HBV incidence are scarce, but emerging evidence suggests ongoing sexual transmission of this disease among HIV-infected adults [10, 11] , who represent a high-risk group for HIV acquisition.
Including HIV-infected persons among the priority groups for HBV vaccination in SSA would require data demonstrating the rate at which new HBV infections occur in this subpopulation. In addition, this dynamic might be affected by ART since it often includes medications like lamivudine (3TC) and tenofovir (TDF) that are also active against HBV and might prevent HBV infection. The aim of this study was to measure the incidence of HBV and to test the hypothesis that ART reduces HBV incidence by exploring risk factors associated with HBVamong the HIV-infected individuals in Uganda.
Methods

Study participants
The study was conducted at the Rakai Health Sciences Program (RHSP) -a large HIV research and treatment center in rural south-western Uganda. The RHSP, through its longitudinal Rakai Community Cohort Study (RCCS), performs population-based surveys in 50 communities at approximately 18-month intervals. In each survey, sera and demographic data are collected from over 14 000 individuals aged 15-49 years, with the primary purpose of monitoring trends of HIV infection in this region. From the RCCS, we identified 944 HIVinfected individuals who had archived sera that had been obtained during at least four RCCS survey rounds conducted between September 2003 and March 2015. We screened the 944 baseline samples for evidence of HBV exposure using the hepatitis B core antibody (anti-HBc) serological marker. Participants who tested anti-HBc-positive at baseline were excluded from this study, whereas those who tested negative were included in the study. Their serum samples collected over 3-7 survey rounds after the baseline survey were serially tested for both anti-HBc and hepatitis B surface antigen (HBsAg) at each survey round with an available sample or until these markers became positive. HBV seroconverters had their baseline sera tested for HBsAg to confirm that they were HBsAg-negative at baseline.
The testing for anti-HBc and HBsAg was performed by EIA technique (Murex Biotech Limited, Dartford, UK). The time of HBV incidence was defined as the median date between the last anti-HBc/HBsAg-negative sample and the first positive anti-HBc or HBsAg serum sample. Infection was defined by a positive HBsAg and/or antiHBc test result. 
Outcomes and measurements
The primary outcome was incident HBV infection defined as the sero-conversion to either anti-HBc or HBsAg, or both. Exposures evaluated as risk factors for HBV acquisition included sociodemographic and clinical factors; age, sex as fixed baseline characteristics, and occupation, marital status, number of sexual partners, ART, CD4 þ T-cell count, and HIV viral load as timevarying covariates at each survey round. Only viral loads within 12 months of the survey round and CD4 þ cell counts within 6 months of the survey round were included in the analysis.
Statistical analysis
Exact Poisson incidence methods were used to estimate the incidence of HBV with 95% confidence intervals (CIs), whereas the Cox proportional regression methods accounting for time-updated exposure variables were used to estimate adjusted hazard ratios (HRs) of ART use and other confounders. Cumulative hazards of infection by age and ART use were estimated with the KaplanMeier method and compared with the log-rank test. Person time of exposure for the nonconverters was computed as the time from the baseline HBV-negative test date to the last negative test date, and as the time from baseline HBV-negative test date to the mid-point of the last negative HBV result and the first HBV-positive test date for the sero-converters. Subanalyses for estimating the effect of single or dual HBV active drugs and suppressed viral load (i.e. viral load <400 copies/ml) were performed. Data were analyzed using STATA software 14 package (StataCorp, College Station, Texas, USA).
Results
The participant selection process is summarized in Fig. 1 . Of the 944 individuals who were eligible for screening, 447 (47%) were either previously or currently infected with HBV at the time of baseline serum sampling; the remaining 497 (53%) who tested negative for the antiHBc marker were subsequently enrolled.
The study population was mainly composed of young individuals, median age 30 [interquartile range (IQR) 25-34], women (71%), and those with preserved CD4 þ T-cell count, median 446/ml (IQR 251-630). The majority (70%) reported one sexual partner in the past year. In contrast, the HBV-infected individuals at baseline were more likely to be older, male, currently or previously married, and to have had at least two partners in the past year (Table 1 ).
Only 4% (22/497) patients were on ART at baseline and an additional 53% (265/497) initiated ART during the course of the study, contributing 2054 person-years of ART use of the total 3342 person-years in the study representing 62% of the total observation time (Fig. 2) . Of the patients who were on ART, 69% (199/287) had documented ART regimen information and 91% (262/ 287) had viral load data within 1 year of a study visit. Among participants with documentation of ART regimen, use of 3TC without TDF was most common (1215 person-years, comprising 85% of all ART use personyears), the combination of 3TC and TDF was used for 213 person-years (14.9 of recorded person-years), and neither 3TC nor TDF were included in the regimens of only 4 person-years (0.3%).
During the study period, 39 participants seroconverted to anti-HBc, had detectable HBsAg, or both. Overall, the 497 participants accrued 3342 person-years during which 39 infections (8 positives for both HBsAg and anti-HBc, 3 for HBsAg only, and 28 for anti-HBc only) occurred, yielding an incidence 1.17/100 (95% CI 0.8-1.6) person-years.
Hepatitis B virus incidence was higher in persons who were younger (Table 2) . Among those 15-29 years old, incident HBV infection was more than three-fold higher than for those who were 40-50 years of age (aHR 3.24, 95% CI1.2-9.0). There were no statistically significant differences by sex, occupation, marital status, number of sex partners, duration on ART, or baseline CD4 þ cell count.
Hepatitis B virus incidence was significantly lower with ARTuse: 0.49 /100 person-years with ARTuse and 2.25/ 100 person-years in the absence of ART (aHR 0.25, 95% CI 0.1-0.5, P < 0.001). HBV incidence was also lower in persons whose HIV RNA was suppressed (indication of receipt and adherence to ART). The incidence was 0.6/ 100 person-years in those with HIV RNA 400 copies/ml or less and 4.0/100 person-years in those with more than 400 copies/ml (aHR 6.4, 95% CI 2.2-19.0, P < 0.001). On multivariate analysis, the protective association of ART on HBV incidence increased after controlling for viral suppression (HR 0.14, 95% CI 0.027-0.76, P ¼ 0.02), but the association of viral suppression diminished after controlling for the absence of HBV active ART (HR 1.73, 95% CI 0.38-7.93, P ¼ 0.48).
With regard to ART use, 99% (198/199) of ART regimens contained 3TC either as the only HBV-active medication (171) or in combination with TDF (27). Three individuals were on a combined pill of TDF and emtricitabine (FTC), and one was on a regimen that contained no HBV-active medication. No individual was on FTC without TDF. For the purpose of this study, individuals on FTC were analyzed as having received 3TC since the two medications have closely related pharmacological properties. To further explore the effect of ART on incident HBV, the analysis was stratified by whether the ART regimen contained the HBV-active medications 3TC/FTC or TDF as follows: no ART if they had never initiated ART, 3TC-based ART if on a 3TC regimen that did not contain TDF, TDF-based ART if on TDF and either 3TC or FTC, or no HBV-active ART if on a regimen that did not contain either TDF, 3TC, or FTC. HBV incidence significantly differed by 3TC use: 0.58/100 person-years in those taking 3TC compared with 2.25/100 in those not taking 3TC or 784 AIDS 2017, Vol 31 No 6 Two hundred and sixty-two patients had viral load results, and 287 were on ART.
TDF (aHR 0.32, 95% CI 0.1-0.7, P ¼ 0.007) ( Table 3) .
No new HBV infection occurred among individuals during the 213 person-years on TDF and 3TC combination-based ART regimen.
To exclude the possibility of very early HBV infection (in which the HBsAg is detectable and anti-HBc is undetectable), the baseline samples of 39 serocoverters were tested for HBsAg. Thirty-one patients tested negative, whereas eight participants had inadequate sera for this test. ART use remained associated with a lower incidence of HBV infection in a subanalysis in which eight participants were excluded.
Discussion
To the best of our knowledge, this is the first study in SSA to evaluate the incidence of HBV in a HIV-infected adult population and the impact of ART on HBV acquisition. We found that HBV incidence was high in this group and that ART may have a protective role in preventing HBV infections among HIV-infected adults.
The high incidence of HBV infection in this study is consistent with data reported from studies in Europe, USA, and Japan, where MSM and i.v. drug users constitute the high-risk groups for HBV infection. In these studies, incident HBV rates among MSM ranged from 0.12 to 1.49 cases per 100 person-years, but were much lower in the non-MSM individuals, and also the HIV-uninfected counterparts [12, 13] . In the RCCS in rural Uganda, our clinical and epidemiological data suggest that HBV is primarily transmitted through heterosexual contacts rather than MSM or intravenous drug use high-risk groups reported elsewhere.
Recent studies from the European Union and Japan also have suggested a pre-exposure protective effect of HBVactive ART medications, particularly TDF and 3TC [12] [13] [14] . Our study is unique in that it showed a protective effect of 3TC only containing regimens in a population where heterosexual HIV transmission is believed to dominate. HIV viral load suppression on ART was a strong predictor of the protective effect of ART against incident HBV in our study, consistent with earlier findings [14, 15] . The mechanism of this effect could be direct suppression of HBV replication or inhibition of HIV replication, altering the biology of HBVacquisition. Failure to suppress HIV could also be associated with poor adherence and higher risk behaviors that predispose to HBV infection [16] . In this study, the increased protective association of ART after controlling for viral suppression and the reduced effect of viral suppression on HBV incidence after controlling for the absence of HBV-active ART suggest that the protective effect of suppressed HIV viral load is a measure for effectiveness of ART and not a viral load-specific effect.
We found no relationship between the baseline CD4 þ Tcell count and duration on ART with incident infection. These results should be interpreted with caution as few patients in our cohort had T-cell counts below 200 cells/ ml, and baseline T-cell counts were missing in the majority of our included participants.
Incident HBV in our study was inversely related to age. The occurrence of the majority of HBV infections between the 15-29 and the 30-39 age groups supports earlier reports from prevalence studies that suggested that sexual intercourse was yet another important route of HBV disease transmission among SSA adults [10, 11] . In our study, however, only a nonstatistically significant association was detected between incident HBV infection and the number of sex partners in the past year, possibly due to under-reporting of this information by study participants.
Our study has some limitations. We used a convenience sample of HIV-infected individuals with available serum from at least four time points, and retrospectively analyzed sera and data from a cohort that was not originally designed to answer our research question; thus, we had missing and incomplete data on some study parameters such as HBV disease risk factors. However, since the blood samples, and sociodemographic and clinical parameters were collected prospectively from a community cohort, and serum sample decay (in relation to HBV serological studies) is unlikely to have occurred, our study findings are more reflective of the community HBV incidence than hospital-based studies. Baseline serum samples were tested for anti-HBc and not for anti-HBs. There is no universal adult vaccination program against HBV in Uganda and the childhood vaccination under the Uganda national expanded program on immunization began in 2002, it is highly unlikely that our study participants, aged 15-49 years, could have acquired immunity to HBV through vaccination.
In conclusion, we find that there is ongoing HBV transmission among HIV-infected adults in SSA. The overall high incidence of HBV in this population and the protective association of ART demonstrate yet another potential benefit to expanding the ART rollout throughout SSA, and possibly initiating ART at time of HIV diagnosis. The findings also suggest HBV vaccination of HIV-infected persons should be integrated into HIV treatment programs in these highly endemic regions.
